CCNI

Summary

CCNI (cyclin I, HGNC:1595) is a protein-coding gene on chromosome 4q21.1, encoding Cyclin-I (Q14094).

The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin shows the highest similarity with cyclin G. The transcript of this gene was found to be expressed constantly during cell cycle progression.

Source: NCBI Gene 10983 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 45 total
• Druggable target: yes
• MANE Select transcript: NM_006835

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1595
Approved symbol	CCNI
Name	cyclin I
Location	4q21.1
Locus type	gene with protein product
Status	Approved
Aliases	CCNI1
Ensembl gene	ENSG00000118816
Ensembl biotype	protein_coding
OMIM	618783
Entrez	10983

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 26 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000237654, ENST00000504697, ENST00000505609, ENST00000506614, ENST00000507788, ENST00000511943, ENST00000513774, ENST00000515468, ENST00000515790, ENST00000718433, ENST00000887836, ENST00000887837, ENST00000887838, ENST00000887839, ENST00000887840, ENST00000887841, ENST00000887842, ENST00000887843, ENST00000887844, ENST00000912006, ENST00000912007, ENST00000912008, ENST00000912009, ENST00000950255, ENST00000950256, ENST00000950257, ENST00000950258, ENST00000950259, ENST00000950260, ENST00000950261

RefSeq mRNA: 10 — MANE Select: NM_006835 NM_001348132, NM_001348133, NM_001348134, NM_001348135, NM_001348136, NM_001348137, NM_001348138, NM_001348139, NM_001348140, NM_006835

CCDS: CCDS3580

Canonical transcript exons

ENST00000237654 — 7 exons

Exon	Start	End
ENSE00001077925	77047155	77048662
ENSE00001077926	77075472	77075989
ENSE00001077929	77055150	77055380
ENSE00003481500	77058507	77058635
ENSE00003579014	77056249	77056323
ENSE00003683884	77055962	77056102
ENSE00004035076	77066249	77066405

Expression profiles

Bgee: expression breadth ubiquitous, 308 present calls, max score 99.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 195.2465 / max 2235.3759, expressed in 1826 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52688	171.4228	1826
52687	17.3018	1778
52689	1.7090	919
52685	1.5138	976
52684	0.6379	429
203254	0.6333	358
203251	0.5354	290
203253	0.4785	228
203256	0.3585	172
203255	0.2918	118

Top tissues by expression

308 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
paraflocculus	UBERON:0005351	99.85	gold quality
cortical plate	UBERON:0005343	99.75	gold quality
parotid gland	UBERON:0001831	99.71	gold quality
ganglionic eminence	UBERON:0004023	99.65	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	99.64	gold quality
colonic epithelium	UBERON:0000397	99.61	gold quality
postcentral gyrus	UBERON:0002581	99.61	gold quality
parietal lobe	UBERON:0001872	99.60	gold quality
blood vessel layer	UBERON:0004797	99.60	gold quality
Brodmann (1909) area 46	UBERON:0006483	99.57	gold quality
caput epididymis	UBERON:0004358	99.55	gold quality
superficial temporal artery	UBERON:0001614	99.51	gold quality
cauda epididymis	UBERON:0004360	99.51	gold quality
nipple	UBERON:0002030	99.50	gold quality
cardia of stomach	UBERON:0001162	99.48	gold quality
endometrium epithelium	UBERON:0004811	99.48	gold quality
cartilage tissue	UBERON:0002418	99.47	gold quality
adult organism	UBERON:0007023	99.47	gold quality
urethra	UBERON:0000057	99.46	gold quality
pons	UBERON:0000988	99.45	gold quality
corpus epididymis	UBERON:0004359	99.44	gold quality
ventricular zone	UBERON:0003053	99.43	gold quality
orbitofrontal cortex	UBERON:0004167	99.43	gold quality
oocyte	CL:0000023	99.39	gold quality
pylorus	UBERON:0001166	99.39	gold quality
type B pancreatic cell	CL:0000169	99.35	gold quality
mammalian vulva	UBERON:0000997	99.35	gold quality
mammary duct	UBERON:0001765	99.35	gold quality
frontal pole	UBERON:0002795	99.33	gold quality
pericardium	UBERON:0002407	99.32	gold quality

Single-cell (SCXA)

Detected in 25 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	3076.73
E-GEOD-124263	yes	2601.83
E-GEOD-137537	yes	2229.12
E-HCAD-4	yes	95.81
E-HCAD-11	yes	51.68
E-CURD-88	yes	33.09
E-CURD-122	yes	32.21
E-GEOD-134144	yes	31.76
E-MTAB-9543	yes	20.78
E-CURD-112	yes	11.14
E-MTAB-10042	yes	10.07
E-GEOD-125970	yes	7.38
E-MTAB-7249	no	6912.64
E-MTAB-9154	no	2941.00
E-MTAB-10485	no	2324.38

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting CCNI, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-4804-3P	99.65	67.78	866
HSA-MIR-7156-5P	99.64	68.81	1369
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-6758-3P	99.57	67.55	1078
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-4273	99.45	67.93	1206
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-133A-3P	99.27	71.53	1270
HSA-MIR-133B	99.27	71.53	1270
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-449B-3P	99.20	67.24	1047
HSA-MIR-3074-5P	98.82	66.56	1414
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-4720-3P	98.50	68.88	988
HSA-MIR-4662A-5P	98.48	67.18	1007

Literature-anchored findings (GeneRIF, showing 4)

• The increased levels of cyclin I and GDI2 found to be associated with pancreatic carcinoma were further confirmed by Western blot analyses in an independent series of serum samples and/or pancreatic juice samples (PMID:17507299)
• Knockdown of Cyclin I induced cell cycle arrest at S/G2/M phases. (PMID:23907122)
• A cyclin I-Cdk5 complex forms a critical antiapoptotic factor in the process of generating cisplatin resistance in cervical cancer. (PMID:26698249)
• CDK6 is activated by the atypical cyclin I to promote E2F-mediated gene expression and cancer cell proliferation. (PMID:37081792)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccni	ENSDARG00000068214
mus_musculus	Ccni	ENSMUSG00000063015
rattus_norvegicus	Ccni	ENSRNOG00000002125
drosophila_melanogaster	CycB	FBGN0000405
drosophila_melanogaster	CycD	FBGN0010315
drosophila_melanogaster	CycE	FBGN0010382
caenorhabditis_elegans		WBGENE00000865
caenorhabditis_elegans		WBGENE00000866
caenorhabditis_elegans	cyb-2.2	WBGENE00000867
caenorhabditis_elegans		WBGENE00000870
caenorhabditis_elegans	cye-1	WBGENE00000871

Paralogs (18): CCNE1 (ENSG00000105173), CCNP (ENSG00000105219), CCNJ (ENSG00000107443), CCND1 (ENSG00000110092), CCND3 (ENSG00000112576), CCNG1 (ENSG00000113328), CCND2 (ENSG00000118971), CCNA1 (ENSG00000133101), CCNB1 (ENSG00000134057), CCNJL (ENSG00000135083), CCNG2 (ENSG00000138764), CCNA2 (ENSG00000145386), CCNB3 (ENSG00000147082), CCNO (ENSG00000152669), CCNB2 (ENSG00000157456), CCNF (ENSG00000162063), CCNE2 (ENSG00000175305), CCNI2 (ENSG00000205089)

Protein

Protein identifiers

Cyclin-I — Q14094 (reviewed: Q14094)

All UniProt accessions (6): Q14094, D6RDK3, D6REZ3, D6RG12, D6RH01, H0YA27

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus membrane.

Tissue specificity. Highest levels in adult heart, brain and skeletal muscle. Lower levels in adult placenta, lung, kidney and pancreas. Also high levels in fetal brain and lower levels in fetal lung, liver and kidney. Also abundant in testis and thyroid.

Similarity. Belongs to the cyclin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14094-1	1	yes
Q14094-2	2

RefSeq proteins (10): NP_001335061, NP_001335062, NP_001335063, NP_001335064, NP_001335065, NP_001335066, NP_001335067, NP_001335068, NP_001335069, NP_006826* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006671	Cyclin_N	Domain
IPR013763	Cyclin-like_dom	Domain
IPR036915	Cyclin-like_sf	Homologous_superfamily
IPR039361	Cyclin	Family

Pfam: PF00134

UniProt features (8 total): sequence conflict 3, chain 1, region of interest 1, compositionally biased region 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14094-F1	72.93	0.46

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 266 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_UP, PAX4_01, TGCGCANK_UNKNOWN, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_CELL_CYCLE_PHASE_TRANSITION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MORF_HDAC1, HSIAO_HOUSEKEEPING_GENES, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_DN, DARWICHE_PAPILLOMA_RISK_HIGH_DN, DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN, GOBP_MALE_GAMETE_GENERATION, WOO_LIVER_CANCER_RECURRENCE_UP, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP

GO Biological Process (2): G1/S transition of mitotic cell cycle (GO:0000082), spermatogenesis (GO:0007283)

GO Molecular Function (2): cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538), protein binding (GO:0005515)

GO Cellular Component (5): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), nucleus (GO:0005634), cytoplasm (GO:0005737), nuclear membrane (GO:0031965), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G1/S phase transition	1
developmental process involved in reproduction	1
male gamete generation	1
cyclin-dependent protein serine/threonine kinase activity	1
cyclin-dependent protein kinase regulator activity	1
binding	1
serine/threonine protein kinase complex	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
nucleus	1
nuclear envelope	1
organelle membrane	1

Protein interactions and networks

STRING

1826 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCNI	AZIN1	O14977	580
CCNI	CDK5	Q00535	571
CCNI	GRIA2	P42262	461
CCNI	GREB1	Q4ZG55	461
CCNI	NEIL1	Q96FI4	455
CCNI	CCNL2	Q96S94	439
CCNI	CYFIP2	Q96F07	424
CCNI	VCY	O14598	418
CCNI	TOR1B	O14657	418
CCNI	FRS2	Q8WU20	398
CCNI	IGFBP7	Q16270	385
CCNI	EPB41L5	Q9HCM4	385
CCNI	KCNA1	Q09470	379
CCNI	TMEM63B	Q5T3F8	378
CCNI	GRIA3	P42263	374

IntAct

24 interactions, top by confidence:

A	B	Type	Score
CDK5	FIBP	psi-mi:“MI:0914”(association)	0.840
CDK5	CCNI	psi-mi:“MI:0915”(physical association)	0.750
CCNI	CDK5	psi-mi:“MI:0915”(physical association)	0.750
CDK3	CCNI	psi-mi:“MI:0915”(physical association)	0.560
CCNI	ZMYND19	psi-mi:“MI:0915”(physical association)	0.560
CDK6	CCNI	psi-mi:“MI:0915”(physical association)	0.560
CDK16	CCNI	psi-mi:“MI:0915”(physical association)	0.370
CDC25A	CCNI	psi-mi:“MI:0915”(physical association)	0.370
CCNI	IL1RAP	psi-mi:“MI:0915”(physical association)	0.370
CCNI	KRT18	psi-mi:“MI:0915”(physical association)	0.370
AKT1	CCNI	psi-mi:“MI:0915”(physical association)	0.370
CCNI	CEP63	psi-mi:“MI:0915”(physical association)	0.000
CEP63	CCNI	psi-mi:“MI:0915”(physical association)	0.000
CCNI	CDK6	psi-mi:“MI:0915”(physical association)	0.000
CCNI	ZMYND19	psi-mi:“MI:0915”(physical association)	0.000
cya	CCNI	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (22): CCNI (Affinity Capture-RNA), CCNI (Affinity Capture-MS), CCNI (Two-hybrid), CCNI (Two-hybrid), CCNI (Two-hybrid), CDK5 (Two-hybrid), ZMYND19 (Two-hybrid), CDK3 (Two-hybrid), CCNI (Two-hybrid), CCNI (Affinity Capture-RNA), CDK5 (Affinity Capture-MS), CCNI (Negative Genetic), CCNI (Affinity Capture-MS), CCNI (Affinity Capture-MS), CCNI (Affinity Capture-MS)

ESM2 similar proteins: A0A494C0Z2, A0A494C191, A1L3C1, A2RRU4, A4Q9F3, A6NJR5, A6NLX3, A6NNV3, A6QM06, A6QNT4, D4A6L0, E1BBQ2, E9PGG2, O00255, O60320, O88559, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, P29590, P40338, P56726, P97260, Q0P5I0, Q12770, Q14094, Q32L49, Q495Y7, Q5IBH6, Q5MJ68, Q5MNU5, Q5Q9Z2, Q5RDC3, Q5T848, Q69Z89

Diamond homologs: O08918, P13351, P24868, P24869, P25011, P25012, P25322, P30183, P30278, P30279, P30280, P39950, P46277, P46278, P51945, P51959, Q04827, Q0JIF2, Q0P5D3, Q14094, Q16589, Q39068, Q39069, Q52QT8, Q5E9I1, Q5R5D0, Q61456, Q6AY13, Q6ZMN8, Q8WNW2, Q92161, Q95TJ9, Q9Z2V9, O01501, O15995, O42575, O48790, O96020, P04962, P0C242

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 12 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
cell division	5	23.1×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

933 predictions. Top by Δscore:

Variant	Effect	Δscore
4:77055960:A:AC	donor_gain	1.0000
4:77055961:C:CC	donor_gain	1.0000
4:77058632:CATT:C	acceptor_gain	1.0000
4:77066243:CATTA:C	donor_loss	1.0000
4:77066244:ATTAC:A	donor_loss	1.0000
4:77066245:TTAC:T	donor_loss	1.0000
4:77066246:TACCT:T	donor_loss	1.0000
4:77066406:CT:C	acceptor_loss	1.0000
4:77075485:T:TA	donor_gain	1.0000
4:77048669:C:CT	acceptor_gain	0.9900
4:77048670:A:T	acceptor_gain	0.9900
4:77055376:TGGAA:T	acceptor_gain	0.9900
4:77055381:C:CC	acceptor_gain	0.9900
4:77055948:T:TA	donor_gain	0.9900
4:77056013:AT:A	donor_gain	0.9900
4:77056014:T:C	donor_gain	0.9900
4:77056321:AGCC:A	acceptor_loss	0.9900
4:77056322:GCC:G	acceptor_loss	0.9900
4:77056323:CCTAA:C	acceptor_loss	0.9900
4:77056324:CTAAA:C	acceptor_loss	0.9900
4:77056325:T:G	acceptor_loss	0.9900
4:77058500:CACTT:C	donor_loss	0.9900
4:77058501:ACTT:A	donor_loss	0.9900
4:77058502:CTTAC:C	donor_loss	0.9900
4:77058503:TTACC:T	donor_loss	0.9900
4:77058504:TAC:T	donor_loss	0.9900
4:77058634:TT:T	acceptor_gain	0.9900
4:77058634:TTC:T	acceptor_loss	0.9900
4:77058635:TCT:T	acceptor_loss	0.9900
4:77058636:C:CC	acceptor_gain	0.9900

AlphaMissense

2483 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:77056017:A:G	L135P	1.000
4:77056029:T:A	E131V	1.000
4:77056031:C:A	M130I	1.000
4:77056031:C:G	M130I	1.000
4:77056031:C:T	M130I	1.000
4:77056267:C:A	K100N	1.000
4:77056267:C:G	K100N	1.000
4:77056285:A:C	C94W	1.000
4:77048634:C:G	R240P	0.999
4:77055216:A:C	S208R	0.999
4:77055216:A:T	S208R	0.999
4:77055218:T:G	S208R	0.999
4:77056001:C:A	W140C	0.999
4:77056001:C:G	W140C	0.999
4:77056003:A:G	W140R	0.999
4:77056003:A:T	W140R	0.999
4:77056028:C:A	E131D	0.999
4:77056028:C:G	E131D	0.999
4:77056032:A:C	M130R	0.999
4:77056034:T:A	R129S	0.999
4:77056034:T:G	R129S	0.999
4:77056035:C:A	R129I	0.999
4:77056035:C:G	R129T	0.999
4:77056274:G:T	A98D	0.999
4:77056275:C:G	A98P	0.999
4:77056286:C:T	C94Y	0.999
4:77056287:A:G	C94R	0.999
4:77056288:G:C	S93R	0.999
4:77056288:G:T	S93R	0.999
4:77056290:T:G	S93R	0.999

dbSNP variants (sampled 300 via entrez): RS10000115 (4:77069590 T>C,G), RS1000044096 (4:77066034 G>A), RS1000098133 (4:77050681 T>C,G), RS1000136644 (4:77075572 T>A,C,G), RS1000213747 (4:77069080 T>C), RS1000218805 (4:77049526 A>G), RS1000299061 (4:77075478 C>CTCCTCT), RS1000339970 (4:77056992 T>C), RS1000415647 (4:77059936 TCAA>T), RS1000564268 (4:77066007 G>A), RS10005701 (4:77063615 G>A,C,T), RS10006033 (4:77047041 T>C), RS1000904606 (4:77074719 T>A,C), RS1000954554 (4:77067813 A>G), RS1000960844 (4:77072824 G>A)

Disease associations

OMIM: gene MIM:618783 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067138 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 2 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.01	Kd	9830	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148016: Binding affinity to human CCNI incubated for 45 mins by Kinobead based pull down assay	kd	9.8301	uM

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, affects cotreatment, decreases expression	5
bisphenol A	affects expression, increases expression, affects cotreatment, decreases expression	4
sodium arsenite	decreases expression, increases expression	2
cobaltous chloride	decreases expression, increases expression	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression, decreases expression	2
Cyclosporine	increases expression	2
Particulate Matter	increases abundance, increases expression	2
GSK-J4	increases expression	1
bisphenol F	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
glycidamide	increases expression	1
chloropicrin	affects expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
bisphenol S	affects cotreatment, decreases expression	1
3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid	decreases expression	1
Sunitinib	increases expression	1
Vorinostat	decreases expression	1
Acetaminophen	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Coumestrol	decreases expression	1
Dexamethasone	decreases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Dust	decreases expression	1
Estradiol	affects expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651058	Binding	Binding affinity to human CCNI incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2TN	Abcam HEK293T CCNI KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.